Roivant joins forces with Korea’s iNtRON Bio to fight superbugs; Evotec inks deal to leverage AI to develop drugs
OMass Therapeutics, which was spun out of Oxford in 2016, has secured £14 million in a Series A round of funding led by Syncona, the life sciences investment arm of the Wellcome Trust that has also invested in another Oxford spinout called Nightstar Therapeutics. OMass uses mass spectrometry platforms to discover and develop therapeutics…
MORERelated News
Introducing Fierce Biotech’s 2024 Fierce 15 – OMass Therapeutics
August 5, 2024
What makes OMass fierce: You can’t fault OMass for its ambition. The company may still be in preclinical development, but it...
Dame Carol Robinson to receive Lifetime Achievement Award for groundbreaking protein analysis work
June 25, 2024
The European Patent Office (EPO) has announced that Dame Carol Robinson, Professor of Chemistry at the University of Oxford, will receive...
5 Pharmaceutical Companies in the UK to Know
March 11, 2024
OMass uses high-resolution mass spectrometry to study protein assemblies and discover new medicines. Its spectrometry platform, called OdyssION, enables better visualization...
